How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?

N Rajoriya, C Combet, F Zoulim, HLA Janssen - Journal of hepatology, 2017 - Elsevier
Chronic hepatitis B virus (HBV) infection remains a global problem. Several HBV genotypes
exist with different biology and geographical prevalence. Whilst the future aim of HBV …

Interferon and hepatitis B: current and future perspectives

J Ye, J Chen - Frontiers in Immunology, 2021 - frontiersin.org
Chronic hepatitis B virus (HBV) infection remains a major health burden worldwide for which
there is still no effective curative treatment. Interferon (IFN) consists of a group of cytokines …

[HTML][HTML] HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon

P Mutz, P Metz, FA Lempp, S Bender, B Qu… - Gastroenterology, 2018 - Elsevier
Background & Aims Hepatitis C virus (HCV) infection is sensitive to interferon (IFN)-based
therapy, whereas hepatitis B virus (HBV) infection is not. It is unclear whether HBV escapes …

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B

F Lebossé, B Testoni, J Fresquet, F Facchetti… - Journal of …, 2017 - Elsevier
Background & Aims Hepatitis B virus (HBV) persistence and the pathobiology of chronic
HBV (CHB) infections result from the interplay between viral replication and host immune …

Functional comparison of interferon‐α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon‐α and interferon‐γ signaling

J Chen, Y Li, F Lai, Y Wang, K Sutter, U Dittmer… - …, 2021 - Wiley Online Library
Background and Aims Interferon (IFN)‐α, composed of numerous subtypes, plays a crucial
role in immune defense. As the most studied subtype, IFN‐α2 has been used for treating …

[PDF][PDF] Hepatitis B virus sensitivity to interferon‐α in hepatocytes is more associated with cellular interferon response than with viral genotype

F Shen, Y Li, Y Wang, V Sozzi, PA Revill, J Liu… - …, 2018 - Wiley Online Library
Interferon‐α (IFN‐α) is used to treat chronic hepatitis B virus (HBV) infection, but only 20%‐
40% of patients respond well. Clinical observations have suggested that HBV genotype is …

[PDF][PDF] Hepatic interferon regulatory factor 6 alleviates liver steatosis and metabolic disorder by transcriptionally suppressing peroxisome proliferator‐activated receptor …

J Tong, CJ Han, JZ Zhang, WZ He, GJ Zhao… - …, 2019 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) has become a worldwide epidemic. A large and
growing unmet therapeutic need has inspired numerous studies in the field. Integrating the …

[HTML][HTML] SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH

L Cano, L Desquilles, G Ghukasyan, G Angenard… - JHEP Reports, 2024 - Elsevier
Background & Aims Metabolic dysfunction-associated steatotic liver disease (MASLD)
results in steatosis, inflammation (steatohepatitis), and fibrosis. Patients with MASLD more …

[PDF][PDF] Exosomal Interferon‐Induced Transmembrane Protein 2 Transmitted to Dendritic Cells Inhibits Interferon Alpha Pathway Activation and Blocks Anti–Hepatitis B …

Y Shi, L Du, D Lv, H Li, J Shang, J Lu, L Zhou… - …, 2019 - Wiley Online Library
The negative regulators in the interferon (IFN) signaling pathway inhibit intrahepatic immune
response, resulting in suboptimal therapeutic response to IFNα treatment in chronic hepatitis …

Intrahepatic transcriptional signature associated with response to interferon-α treatment in the woodchuck model of chronic hepatitis B

SP Fletcher, DJ Chin, L Gruenbaum, H Bitter… - PLoS …, 2015 - journals.plos.org
Recombinant interferon-alpha (IFN-α) is an approved therapy for chronic hepatitis B (CHB),
but the molecular basis of treatment response remains to be determined. The woodchuck …